What is a biologic, and how is it different from a normal drug?

A biologic is a large, precisely-engineered molecule — often an antibody — built to block one specific target, whereas familiar small-molecule drugs act more broadly. The CGRP antibodies for migraine are the pain field's landmark example of how targeting a single molecule can prevent pain.

Did the CGRP migraine drugs really change things?

Yes. Erenumab, approved in 2018, was the first antibody designed to prevent migraine by blocking the CGRP pathway — and the first approved antibody against this kind of receptor. It proved a precisely-targeted biologic can prevent pain, and a whole class of migraine drugs followed.

Is gene therapy for pain real?

It is at the earliest stage. Experimental therapies that turn down the SCN9A / NaV1.7 pain gene have produced durable relief in animals and are only now entering first-in-human trials. The idea is powerful — a one-time treatment at the genetic source — but it is unproven in people and years from routine use.

The Future of Pain Medicine

Biologics & Gene-Targeted Therapy

Instead of broadly dialing down the nervous system, a new generation of treatments targets single, specific molecules in the pain pathway. Antibodies against the CGRP protein transformed migraine prevention — proof that blocking one pain signal can work. Now that precision is reaching further: drugs aimed at nerve-growth factors, and gene therapies designed to quiet the master pain gene, NaV1.7, at its source.

Written from primary sources. Built from the cited references below — independent medical review is pending. Educational information, not medical advice.

Last updated August 26, 2026

The trend in pain drugs: from broad-acting molecules, to antibodies that block a single target, to gene therapies aimed at the pain gene itself.

Most familiar painkillers are small molecules that act broadly across the nervous system — effective, but blunt. The frontier of pain treatment is moving the other way: toward therapies precise enough to block a single molecule, or to reach the gene that makes it.

The migraine breakthrough

The proof that precision works came from migraine. A protein called CGRP helps drive migraine attacks, and in 2018 the FDA approved erenumab — the first antibody designed to block the CGRP pathway and prevent migraine. It was the first approved antibody against its kind of receptor, and it worked: a whole class of CGRP antibodies and oral “gepant” drugs followed. Earlier attempts at small-molecule CGRP blockers had stumbled on liver safety; the precisely-targeted biologic route is what finally broke through. The lesson for all of pain medicine: block the right single molecule, and you can prevent pain.

Targeting the pain amplifiers

Some proteins act like fertilizer for pain signaling. The best-studied is nerve growth factor (NGF). Antibodies that block it — led by tanezumab — clearly relieved osteoarthritis pain, but they also raised the risk of rapidly progressive joint damage, and in 2021 the program was halted after an FDA panel voted against it. The story isn’t over: a newer biologic, LEVI-04, targets a related neurotrophin and, in a 2026 trial, improved pain and function without the joint-damage signal that sank its predecessor. It is a vivid example of how powerful — and how tricky — this target is.

Editing the pain system itself

The most precise frontier is gene therapy. A gene called SCN9A builds the sodium channel NaV1.7, a master switch near the start of the pain pathway — people born without it feel almost no pain. Experimental therapies now use engineered proteins to turn that gene down in the sensory nerves, aiming for long-lasting relief from a single treatment. One such therapy, working through this exact mechanism, has entered its first human trial. It is the earliest of early days, but the ambition is remarkable: quieting pain at its genetic source.

A word on regenerative hype

Not everything marketed as a “biologic” is on equally solid ground. Regenerative treatments such as platelet-rich plasma and stem-cell injections are widely advertised for joint pain, but the evidence that they meaningfully outperform simpler options remains mixed and contested. Genuine biologic breakthroughs and clinics selling hope are both part of this space — telling them apart is exactly what a page like this is for.

Climbing the precision ladder

From broad drugs, to antibodies against one molecule, to therapies that edit the pain gene — the direction is clear even where the science is young. Follow the specific candidates by trial phase in the pain treatment pipeline.

Frequently asked questions

What is a biologic, and how is it different from a normal drug?: A biologic is a large, precisely-engineered molecule — often an antibody — built to block one specific target, whereas familiar small-molecule drugs act more broadly. The CGRP antibodies for migraine are the pain field's landmark example of how targeting a single molecule can prevent pain.
Did the CGRP migraine drugs really change things?: Yes. Erenumab, approved in 2018, was the first antibody designed to prevent migraine by blocking the CGRP pathway — and the first approved antibody against this kind of receptor. It proved a precisely-targeted biologic can prevent pain, and a whole class of migraine drugs followed.
Is gene therapy for pain real?: It is at the earliest stage. Experimental therapies that turn down the SCN9A / NaV1.7 pain gene have produced durable relief in animals and are only now entering first-in-human trials. The idea is powerful — a one-time treatment at the genetic source — but it is unproven in people and years from routine use.

References

1.Discovery of Aimovig (erenumab), the first FDA-approved anti-CGRP antibody — NCBI / PMC
2.Lilly & Pfizer halt tanezumab (anti-NGF) after FDA rejection — FierceBiotech
3.LEVI-04 (NT-3 inhibitor) Phase 2 trial in knee osteoarthritis — The Lancet
4.ST-503 — NaV1.7 gene-therapy Phase 1 (NCT06980948) — ClinicalTrials.gov

The pain treatment pipelineTrack these biologics and gene therapies by phase.The three types of painWhy matching the target to the mechanism matters.

This page is educational and is not a substitute for professional medical advice. Talk with a qualified clinician about your own situation. Pain Medicine does not provide treatment or dosing guidance.